Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
FDA: Management of chronic stable angina (vasospastic and exertional), treatment of hypertension.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites are inactive.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
>95% bound to albumin, alpha-1-acid glycoprotein, and lipoproteins
92-98% bound primarily to albumin.
0.2-0.6 L/kg; suggests limited tissue distribution; higher in hepatic cirrhosis
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
IV: 100%; not available orally in this formulation
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
GFR < 30 m L/min: initial dose 2.5 mg/hr; titrate cautiously. No adjustment for GFR ≥ 30.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Child-Pugh Class A: no adjustment. Class B: reduce initial dose by 50%. Class C: avoid use.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Safety and efficacy not established; no standard dosing recommendations.
Safety and efficacy not established; use is not recommended in pediatric patients.
Start at lower end of dosing range (2.5-3 mg/hr); titrate slowly due to increased sensitivity.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None.
No FDA black box warning.
Hypotension and reflex tachycardia may occur, especially in patients on beta-blockers.,Use caution in patients with congestive heart failure or impaired ventricular function.,May cause worsening of angina on abrupt withdrawal.,Hepatic impairment may increase drug levels; dose adjustment may be needed.,Peripheral edema is common but not due to fluid retention.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to nicardipine or any component of the formulation.,Advanced aortic stenosis.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Avoid grapefruit and grapefruit juice as they may increase nicardipine levels. High fat meals can affect absorption, but since this is IV, dietary restrictions primarily relate to dextrose content for diabetics. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
First trimester: No adequate human studies; animal studies show no teratogenic effects at therapeutic doses. Second and third trimesters: Potential for fetal hypoxia, hypotension, and growth restriction due to maternal hypotension; avoid use for tocolysis.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Nicardipine is excreted in human milk; estimated infant dose <2% of maternal weight-adjusted dose. M/P ratio: 1.2. Caution advised; monitor infant for hypotension and cardiovascular effects.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
No specific dose adjustment required based on pharmacokinetic changes; use lowest effective dose; monitor for maternal hypotension and fetal effects.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
CARDENE (nicardipine) in 4.8% dextrose is a dihydropyridine calcium channel blocker used for IV treatment of hypertension. It is light-sensitive; protect from light. Titrate dose by 1-2 mg/hour increments every 5 minutes up to target blood pressure. Do not mix with sodium bicarbonate or lactated Ringer's. Use with caution in patients with coronary artery disease due to reflex tachycardia, and in hepatic impairment as metabolism is hepatic. May cause peripheral edema; monitor for worsening heart failure.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
This medication is given intravenously to lower blood pressure; you will be closely monitored.,Inform your healthcare provider if you have a history of heart disease, liver problems, or if you are pregnant or breastfeeding.,You may experience headache, dizziness, or flushing; report these if severe.,Avoid alcohol consumption while on this medication as it may increase side effects.,This solution contains dextrose; notify your doctor if you have diabetes or need to restrict sugar intake.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs ADALAT CC, answered by our medical review team.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is a Calcium Channel Blocker that works by Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is: Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is classified as Category C. First trimester: No adequate human studies; animal studies show no teratogenic effects at therapeutic doses. Second and third trimesters: Potential for fetal hypoxia, hypotension, . ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.